BriaCell DSMB flags no safety issues, backs continued Phase 3 metastatic breast cancer trial of Bria-IMT plus checkpoint inhibitor

• An independent safety board recommended continuing BriaCell’s Phase 3 Bria-ABC trial of Bria-IMT with an immune checkpoint inhibitor.
• The review reported no safety concerns so far, supporting the program’s risk profile as enrollment and treatment continue.
• No new efficacy results were presented; the update focused on safety oversight rather than trial outcomes.
• The study runs under FDA Fast Track designation, positioning the asset for a potentially faster regulatory path if later data support it.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140730PRIMZONEFULLFEED9825423) on September 14, 2026, and is solely responsible for the information contained therein.